Trusted Resources: People & Places
Online groups, photo galleries and blogs
Julie Eisengart, PhD, LP
Researcher Associate Professor
Department of Pediatrics
University of Minnesota
100 Church Street SE
Minneapolis, Minnesota, United States
Dr. Julie Eisengart is an Associate Professor in the Department of Pediatrics and the Director of the Neurodevelopmental Program in Rare Disease. As a Pediatric Neuropsychologist, she specializes in rare neurodegenerative disorders of childhood as well as a range of complex medical conditions, and she works with patients from infancy to young adulthood. Her clinical interests include assessing the strengths and needs of children affected by complex medical diagnoses, throughout their medical journeys, to optimize whole-child, whole-family care and supports. As a clinical supervisor and mentor, she values her role in training future psychologists and supporting their development into independent, balanced professionals.
Dr. Eisengart’s research interests include lysosomal storage disorders like Mucopolysaccharidosis (MPS), natural histories and treatment outcomes of rare diseases involving the central nervous system. She focuses on the changing relationships between brain structure, biochemical abnormalities, and brain function in rare disease, with the goal of predicting outcomes and improving supportive planning. She has been heavily involved in examining outcomes of early diagnosis, newborn screening, and/or novel therapies for rare disease. Her research extends to defining and measuring aspects of disease that are under-represented in the clinical and research communities but are important and meaningful to patients and their families, such as neurobehavioral symptoms and the caregiver lived experience.
Representative Publications:
Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology
Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement
The Natural History of Neurocognition in MPS Disorders: A Review
Issues of COVID-19-Related Distance Learning for Children With Neuronopathic Mucopolysaccharidoses
BookmarkRelated Content
-
Paul Harmatz, MDDr. Paul Harmatz is a Professor in Resid...
-
Progression of Cardiovascular Manifestations in Adults and Children With Mucopolysaccharidoses With and Without Enzy...Cardiovascular involvement is among the ...
-
Genome Editing in Mucopolysaccharidoses and MucolipidosesMucopolysaccharidoses (MPS) and mucolipi...
-
Understanding Mucopolysaccharidosis Type VII (MPS VII) or Sly SyndromeMPS VII, also called Sly syndrome, is a ...
-
Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A SyndromeMucopolysaccharidosis type IVA (MPS IVA ...
-
iPS-Derived Neural Stem Cells for Disease Modeling and Evaluation of Therapeutics for Mucopolysaccharidosis Type IIMucopolysaccharidosis type II (MPS II), ...
-
In Silico Analysis of Potential Off-Target Sites to Gene Editing for Mucopolysaccharidosis Type I Using the CRISPR/C...Mucopolysaccharidosis type I (MPS I) is ...
